Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Apex Labs CBD Launches Pico IV, the World's First Sterile CBD IV Solution


News provided by

Apex Labs CBD/Pico IV

Jul 25, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Pico IV
Pico IV

Pico IV is available to IV Therapy Centers across the US as a new way for customers to enjoy the benefits of CBD.

SACRAMENTO, Calif., July 25, 2023 /PRNewswire-PRWeb/ -- Apex Labs CBD has developed a groundbreaking new product that combines the world CBD with intravenous (IV) therapy. By pioneering a new form of technology, the team at Apex Labs CBD was able to reduce the size of the CBD molecule to make it both water-soluble and small enough to pass through a sterile filter, making it safe for intravenous use. This first-of-its-kind sterile CBD solution can bring the many benefits of cannabidiol and the hemp world to IV Therapy Clinics across the country and complement a variety of functional or regenerative medicine offerings.

The intravenous (IV) hydration therapy market has experienced tremendous growth in the last decade and is projected to continue growing over the coming years. It offers a safe and easy way to deliver nutrients and hydration directly into the bloodstream. Some of the most popular IV therapy treatments target everything from skincare and hydration to hangover remedies and overall health and wellness. Pico IV offers the opportunity to supplement these treatments with the unique benefits of CBD, allowing IV Therapy to create custom protocols for their customers.

“Not only is it the merging of two really significant markets in the wellness industry, but it also represents how much potential there is when combining the power of science with one of nature’s greatest gifts." said Joe Young, CEO and co-founder of Apex Labs CBD.

Post this

CBD, or cannabidiol, is one of the many non-psychoactive components naturally derived from the hemp plant. It interacts naturally with the body to support overall health and well-being. It can also help reduce occasional feelings of stress or anxiety, support a healthy sleep cycle, and potentially ease aches or pains due to overexertion.* Pico IV uses the CBD isolate with zero THC from industrial-grown hemp in the USA. Thanks to its legalization in 2018 with the Farm Bill, the CBD industry has been experiencing tremendous growth.

"We were incredibly excited to be able to bring this product to the market," said Joe Young, CEO and co-founder of Apex Labs CBD. "Not only is it the merging of two really significant markets in the wellness industry, but it also represents how much potential there is when combining the power of science with one of nature's greatest gifts. We're proud to offer a new way for people to experience CBD."

The desire for a CBD intravenous solution has been present for years, as other methods of CBD usage, like ingestion, topical or sublingual, don't offer the same levels of system absorption as an IV solution. However, because the CBD molecule was too large to pass through a sterile filtration process, it would result in a non-sterile product. While recent developments in technology led to water-soluble CBD, and more recently, nanoemulsions, Miles Terry, (CSO, co-founder) created patent-pending technology that reduced the molecule size even further down to the size of a picometer, allowing for a sterile filtration process and maximum system absorptions.

Apex Labs CBD values quality and testing throughout the product development process. All products are sent to a third-party testing facility, California-Ag Labs, to test for potency and purity. The comprehensive test reports are published on the website and include test results for microbes, pesticides, metals, potency, mycotoxins, and residual solvents.

Robert Myer, owner of California Ag Labs, stated, "I am so thrilled for this development in the hemp world. I'm a long-time believer in the power of CBD and how it helps the body, naturally. To see this product realized is a dream come true. I believe it will open new doors for people to experience the benefits of CBD for themselves. And that's what we want, to make the best quality CBD more accessible to everyone."

Pico IV is currently available for purchase online after member registration. Each sterile vial has 50ml infused with approximately 200mg of CBD, or cannabidiol, and provides 4 doses at 50mg per dose. You must be a licensed IV therapy provider to purchase. For more information, visit PicoIV.com.

ABOUT APEX LABS CBD:

Founded in 2019, Apex Labs CBD began its mission to create top-quality CBD products on the market that are accessible to all. With a focus on product development, as well as rigorous testing and standards, the product offering grew to include everything from new cannabinoids to innovative product categories, like water-soluble tinctures and beverage enhancers. Apex Labs CBD offers both retail and B2B options, as well as a variety of resource services. With its expansion into the IV Therapy market, Apex Labs CBD will continue to operate with transparency, upholding high standards, all while creating new ways for people to experience the many benefits of CBD.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Media Contact

Anna Osborn, Apex Labs CBD/Pico IV, 855-900-0020, support@picoiv.com

SOURCE Apex Labs CBD/Pico IV

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.